Novavax to Participate in Cowen's 42nd Annual Health Care Conference

Rhea-AI Summary

Novavax (Nasdaq: NVAX) will participate in Cowen's 42nd Annual Healthcare Conference on March 8, 2022, from 9:50 – 10:20 a.m. EST. The session will focus on their recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373. Key company executives, including Filip Dubovsky and John J. Trizzino, will present. A recorded session will be available on the company's website for 90 days post-conference. Novavax is also developing a COVID-influenza combination vaccine currently in clinical trials.

GAITHERSBURG, Md., March 2, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in Cowen's 42^nd Annual Healthcare Conference. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.

Conference Details:
Fireside Chat
Date:		Tuesday, March 8, 2022
Time:		9:50 – 10:20 a.m. Eastern Standard Time (EST)
Cowen Moderator:		Georgi Yordanov, Ph.D.
Novavax participants:		Filip Dubovsky, M.D., Executive Vice President, Chief Medical Officer and John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer
Conference
Event:		Investor Meetings
Date:		Tuesday, March 8, 2022

A replay of the recorded fireside session will be available through the events page of the Company's website at ir.novavax.com for 90 days.

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. NVX-CoV2373, the company's COVID-19 vaccine, has received conditional authorization from multiple regulatory authorities globally, including the European Commission and the World Health Organization. The vaccine is also under review by multiple regulatory agencies worldwide. In addition to its COVID-19 vaccine, Novavax is also currently evaluating a COVID-seasonal influenza combination vaccine in a Phase 1/2 clinical trial, which combines NVX-CoV2373 and NanoFlu, its quadrivalent influenza investigational vaccine candidate. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information, visit www.novavax.com and connect with us on Twitter, LinkedIn, Instagram and Facebook.

Contacts:      
Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
ir@novavax.com

Solebury Trout
Alexandra Roy | 617-221-9197
aroy@soleburytrout.com 

Media
Ali Chartan | 240-720-7804
Laura Keenan Lindsey | 202-709-7521
media@novavax.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-cowens-42nd-annual-health-care-conference-301494394.html

SOURCE Novavax, Inc.

FAQ

When is Novavax participating in Cowen's 42nd Annual Healthcare Conference?

Novavax will participate on March 8, 2022.

What time will Novavax's session at Cowen's conference take place?

The session is scheduled from 9:50 to 10:20 a.m. EST.

Who will represent Novavax at the conference?

Filip Dubovsky and John J. Trizzino will represent Novavax.

What vaccine candidate will be discussed at the conference?

The NVX-CoV2373 COVID-19 vaccine candidate will be discussed.

How can I access the recorded session of Novavax's conference participation?

The recorded session will be available on Novavax's website for 90 days.